Reflux Esophagitis Phase III Study (Initial Treatment)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily
for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in
comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux
Esophagitis at Week 8 according to the Los Angeles classification .